The Female Health Company Receives Order for 4.3 Million FC2 Female Condoms for Papua...

The Female Health Company Receives Order for 4.3 Million FC2 Female Condoms
for Papua New Guinea

CHICAGO, Sept. 2 /PRNewswire-FirstCall/ -- The Female Health Company
(Amex: FHC) which manufactures and markets the FC and FC2 Female Condoms(R),
today announced it has received an order for 4.3 million FC2s from the Papua
New Guinea - Australia HIV and AIDS program. To date, this is the largest
order received for FC2, FHC's second generation female condom. The National
AIDS Council Secretariat will coordinate the distribution of FC2, starting in
October 2008, by the Department of Health and the non-government organization
community.
In Papua New Guinea there is widespread demand for the female condom,
which was first introduced there in the 1990's. Mike Pope, Vice President of
The Female Health Company's UK and Malaysia operations said 'This order is an
indication of FHC's female condom's increasing acceptance as an effective tool
for prevention of HIV'.
Papua New Guinea accounts for 70% of all HIV infections in the Australasia
region. Funding for the FC2 order is from AusAID, the Australian Government's
Overseas Aid Program.
About The Female Health Company
The Female Health Company (FHC), headquartered in Chicago, IL, is the
maker of the FC Female Condom (FC1 and FC2), a revolutionary option offering
women dual protection against both sexually transmitted diseases, including
HIV/AIDS, and unintended pregnancy. FHC was created as a worldwide company in
February 1996 with the purchase of Chartex Resources Ltd., the holder of
exclusive worldwide rights to FC1. The Company holds exclusive product and
technology patents for FC1 in the United States, Australia, Brazil, Canada,
France, Germany, Italy, Spain, the United Kingdom, the People's Republic of
China, South Korea and Japan. Patents are pending for FC2. FHC is the sole
manufacturer and marketer of the FC1 and FC2 female condoms in the world. The
Female Health Company and its partners currently market the Female Condom
under FC Female Condom(R), FC2 Female Condom(R), Reality(R), Femidom(R),
Femy(R), and Care(R) in the rest of the world.
For more information about the Female Health Company visit the Company's
website at http://www.femalehealth.com and http://www.femalecondom.org . If
you would like to be added to the Company's e-mail alert list, please send an
e-mail to FHCInvestor@femalehealthcompany.com .
"Safe Harbor" statement under the Private Securities Litigation Reform Act
of 1995:
The statements in this release which are not historical fact are
"forward-looking statements" as that term is defined in the Private Securities
Litigation Reform Act of 1995. Forward-looking statements in this release may
be identified by the use of forward-looking words or phrases such as
"anticipate," "believe," "could," "expect," "intend," "may," "planned,"
"potential," "should," "will," "would" or the negative of those terms or other
words of similar meaning. These statements are based upon the Company's
current plans and strategies, and reflect the Company's current assessment of
the risks and uncertainties related to its business, and are made as of the
date of this release. The Company assumes no obligation to update any
forward-looking statements contained in this release as a result of new
information or future events, developments or circumstances. Such
forward-looking statements are inherently subject to known and unknown risks
and uncertainties. The Company's actual results and future developments could
differ materially from the results or developments expressed in, or implied
by, these forward-looking statements. Factors that may cause actual results
to differ materially from those contemplated by such forward-looking
statements include, but are not limited to, the following: product demand and
market acceptance; competition in the Company's markets and the risk of new
competitors and new competitive product introductions; the Company's reliance
on its international partners in the consumer sector and on the level of
spending on the female condom by country governments, global donors and other
public health organizations in the global public sector; the economic and
business environment and the impact of government pressures; risks involved in
doing business on an international level, including currency risks, regulatory
requirements, political risks, export restrictions and other trade barriers;
the Company's production capacity; efficiency and supply constraints; and
other risks detailed in the Company's press releases, shareholder
communication and Securities and Exchange Commission filings, including the
Company's Form 10-KSB for the fiscal year ended September 30, 2007. Actual
events affecting the Company and the impact of such events on the Company's
operations may vary from those currently anticipated.
SOURCE The Female Health Company

William R. Gargiulo, Jr., +1-231-526-1244, or Donna Felch, +1-312-595-9123,
both for The Female Health Company